Related Experiment Video

Updated: May 29, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia

Francesca Romana Mauro1, Giuseppe Bandini, Giovanni Barosi

  • 1Dipartimento di Biotecnologie Cellulari ed Ematologia, Università degli Studi La Sapienza, Roma, Italy.

Leukemia Research
|September 3, 2011
PubMed

Insights

Updated guidelines recommend fludarabine, cyclophosphamide, rituximab (FCR) for younger chronic lymphocytic leukemia (CLL) patients. Less toxic options are advised for elderly or unfit individuals, with specific strategies for relapsed or refractory cases based on genetic factors.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Guidelines

Background:

  • The 2006 guidelines for chronic lymphocytic leukemia (CLL) management by SIE, SIES, and GITMO required updating.
  • The GRADE system provides a framework for evidence-based guideline development.

Purpose of the Study:

  • To update the clinical management guidelines for chronic lymphocytic leukemia (CLL).
  • To provide evidence-based recommendations for treatment strategies in various patient subgroups.

Main Methods:

  • Utilized the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system for guideline development.
  • Reviewed and synthesized existing evidence to formulate updated recommendations.

Main Results:

  • Recommended fludarabine, cyclophosphamide, rituximab (FCR) for younger, fit patients without unfavorable genetics (del17p/p53 mutations).
  • Advised less toxic treatments for unfit and elderly patients.
  • Suggested re-treatment with initial therapy (including rituximab) for relapse after 24 months in patients without unfavorable genetics.
  • Recommended allogeneic stem cell transplant (SCT) or experimental treatments for patients with unfavorable genetics or early relapse/refractory disease.

Conclusions:

  • Updated guidelines offer tailored treatment approaches for CLL based on patient fitness, age, genetic markers, and response to prior therapy.
  • These recommendations aim to optimize outcomes and minimize toxicity in chronic lymphocytic leukemia management.

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...